Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-20-3384-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.08 million
Profitability
Miscellaneous
Employees180
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable
Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions
What is Orchard Therapeutics' stock symbol?
Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."
How were Orchard Therapeutics' earnings last quarter?
Orchard Therapeutics PLC - (NASDAQ:ORTX) announced its earnings results on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. The firm had revenue of $1.92 million for the quarter, compared to analyst estimates of $0.53 million. View Orchard Therapeutics' Earnings History.
When is Orchard Therapeutics' next earnings date?
What price target have analysts set for ORTX?
6 brokers have issued twelve-month target prices for Orchard Therapeutics' shares. Their forecasts range from $21.00 to $31.00. On average, they expect Orchard Therapeutics' share price to reach $25.33 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.
What is the consensus analysts' recommendation for Orchard Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.
Has Orchard Therapeutics been receiving favorable news coverage?
Media headlines about ORTX stock have been trending extremely positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Orchard Therapeutics earned a news impact score of 5.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Orchard Therapeutics.
Are investors shorting Orchard Therapeutics?
Orchard Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 2,080,000 shares, a drop of 32.5% from the October 31st total of 3,080,000 shares. Based on an average daily trading volume, of 198,900 shares, the short-interest ratio is currently 10.5 days. Currently, 2.8% of the shares of the company are short sold. View Orchard Therapeutics' Current Options Chain.
Who are some of Orchard Therapeutics' key competitors?
Some companies that are related to Orchard Therapeutics include Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO) and Alector (ALEC).
What other stocks do shareholders of Orchard Therapeutics own?
Who are Orchard Therapeutics' key executives?
Orchard Therapeutics' management team includes the folowing people:
- Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
- Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
- Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
- Ms. Ran Zheng, Chief Technical Officer
- Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54)
When did Orchard Therapeutics IPO?
(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Orchard Therapeutics' major shareholders?
Orchard Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (0.53%), Millennium Management LLC (0.40%), Alps Advisors Inc. (0.20%), Point72 Asset Management L.P. (0.17%), State Street Corp (0.03%) and Barclays PLC (0.02%).
Which institutional investors are selling Orchard Therapeutics stock?
ORTX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc. and Massachusetts Financial Services Co. MA.
Which institutional investors are buying Orchard Therapeutics stock?
ORTX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp and Barclays PLC.
How do I buy shares of Orchard Therapeutics?
Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Orchard Therapeutics' stock price today?
One share of ORTX stock can currently be purchased for approximately $11.97.
How big of a company is Orchard Therapeutics?
Orchard Therapeutics has a market capitalization of $1.15 billion and generates $2.08 million in revenue each year. The company earns $-230,490,000.00 in net income (profit) each year or ($10.22) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.View Additional Information About Orchard Therapeutics.
What is Orchard Therapeutics' official website?
How can I contact Orchard Therapeutics?
Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 44-20-3384-6700.
MarketBeat Community Rating for Orchard Therapeutics (NASDAQ ORTX)
MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote "Outperform" if you believe ORTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
